Role of hypoalbuminemia in the genesis of cardiovascular disease in dialysis patients

Peritoneal Dialysis International

Volumn 19, Issue SUPPL. 2, 1999, Pages

  Kim, Soon Bae ^a   Yang, Won Seok ^a   Park, Jung Sik ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Albumin; Atherosclerosis; Cardiovascular disease; End stage renal disease

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SERUM ALBUMIN; VON WILLEBRAND FACTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPOALBUMINEMIA; KIDNEY DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 0033394636     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901902s23     Document Type: Conference Paper

References (59)

1. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barré PE. Hypoalbuminemia, cardiac morbidity and mortality in end-stage renal disease. J Am Soc Nephrol. 1996; 7:728-36.
2. Churchill DN, Taylor DW, Cook RJ, LaPlante P, Barré P, Cartier P, et al. Canadian hemodialysis morbidity study. Am J Kidney Dis. 1992; 19:214-34.
3. Foley RN, Parfrey PS. Risk factors for cardiac morbidity and mortality in dialysis patients. Curr Opin Nephrol Hypertens. 1994; 3:608-14.
4. Richard JL, Warnet JM, Ducimetiere P. Decreased levels of the albumin-alpha-1-globulin fraction of serum proteins, risk factor for ischemic cardiopathy. Rev Epidemiol Sante Publique. 1985; 33:347-51.
5. Phillips A, Shaper AG, Whincup PH. Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes. Lancet. 1989; 2:1434-6.
6. Kuller LH, Eichner JE, Orchard TJ, Grandits GA, McCallum L, Tracy RP. The relation between serum albumin levels and risk of coronary heart disease in the Multiple Risk Factor Intervention Trial. J Epidemiol. 1991; 134:1266-77.
7. Bernard D, Gouault-Heilmann M, Ansquer JC, Levent M, Ladieu D, Lagrue G. Study of hemostasis factors in nephrotic syndrome. Pathogenic interpretation and therapeutic deductions. Ann Med Interne (Paris). 1977; 128:325-33.
8. Ordonez JD, Hiatt R, Killebrew E, Fireman B. The increased risk of coronary artery disease associated with nephrotic syndrome. Kidney Int. 1993; 37:638-42.
9. Sigurdardottii S, Bhadra E, Coutinho M, Davis I. Hemolytic uremic syndrome - Is low serum albumin an early predictive factor for the development of renal failure and treatment with albumin infusions able to prevent the subsequent development of renal failure? [Abstract]. J Am Soc Nephrol. 1996; 7:1378.
10. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation. 1992; 86:475-82.
11. Hong SY, Yang DH. Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrome. Nephron. 1995; 69:125-30.
12. Yang WS, Kim SB, Min WK, Park S, Lee MS, Park JS. Atherogenic lipid profile and lipoprotein(a) in relation to serum albumin in haemodialysis patients. Nephrol Dial Transplant. 1995; 10:1668-71.
13. Kim SB, Yang WS, Lee SK, Chi HS, Park JS. Effect of increasing serum albumin on haemostatic factors synthesized in the liver in CAPD patients. Nephrol Dial Transplant. 1998; 13:2053-8.
14. Stenvinkel P, Berglund L, Ericsson S, Alvestrand A, Angelin B, Eriksson M. Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome. Eur J Clin Invest, 1997; 27:169-77.
15. Yang WS, Kim SB, Min WK, Park JS. Effect of increasing serum albumin on serum lipoprotein(a) concentration in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1997; 30:507-13.
16. Ross EA, Shah GM, Kashyap ML. Elevated plasma lipoprotein(a) levels and hypoalbuminemia in peritoneal dialysis patients. Int J Artif Organs. 1995; 18:751-6.
17. Prichard S, Cianflone K, Sniderman A. The role of the liver in the pathogenesis of hyperlipidemia in patients with end-stage renal disease treated with continuous ambulatory peritoneal dialysis. Perit Dial Int. 1996; 16(Suppl 1):S207-10.
18. Shoji T, Nishizawa Y, Nishitani H,Yamakawa M, Morii H. Role of hypoalbuminemia and lipoprotein lipase on hyperlipoproteinemia in continuous ambulatory peritoneal dialysis. Metabolism. 1991; 40:1002-8.
19. Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein PA, Mittman N. The uremic dyslipidemia: A cross-sectional and longitudinal study. Am J Kidney Dis. 1992; 20:324-35.
20. Baxter JH, Goodman HC, Allen JC. Effects of albumin infusion on serum lipids and lipoproteins in nephrosis. J Clin Invest. 1961; 40:490-8.
21. Allen JC, Baxter JH, Goodman HC. Effects of dextran, polyvinylpyrrolidone and gamma globulin on the hyperlipidemia of experimental nephrosis. J Clin Invest. 1961; 40:499-508.
22. Farmer JA, Gotto AM Jr. Dyslipidemia and other risk factors for coronary artery disease. In: Braunwald E, ed. Heart Disease. 5th ed. Philadelphia: W.B. Saunders; 1997:1126-60.
23. Kanfer A, Kleinknecht D, Broyer M, Josso F. Coagulation studies in 45 cases of nephrotic syndrome without uremia. Thromb Diathes Haemorrh. 1970; 24:562-71.
24. Kim KJ, Yang WS, Kim SB, Lee SK, Park JS. Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and correlation with serum albumin. Perit Dial Int. 1997; 17:157-61.
25. Pickart LR, Thaler MM. Free fatty acids and albumin as mediators of thrombin-stimulated fibrinogen synthesis. Am J Physiol. 1976; 230:996-1002.
26. Johnson SD, Lucas CE, Gerrick SJ, Ledgerwood AM, Higgins RF. Altered coagulation after albumin supplements for treatment of oligemic shock. Arch Surg. 1979; 114:379-83.
27. Kim SB, Yang WS, Chi HS, Park JS. Effect of increasing serum albumin on plasma D-dimer and von Willebrand factor levels and platelet aggregation in CAPD patients. Am J Kidney Dis. 1999; 33:312-17.
28. Marcus AJ. Platelet activation. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. 1st ed. Philadelphia: Lippincott-Raven; 1996:607-37.
29. Bang NU, Trygstad CW, Schroeder JE, Heidenreich RD, Csicsko BM. Enhanced platelet function in glomerular renal disease. J Lab Clin Med. 1973; 81:651-9.
30. Jorgensen KA, Stoffersen E. On the inhibitory effect of albumin on platelet aggregation. Thromb Res. 1980; 17:13-18.
31. Yoshida N, Aoki N. Release of arachidonic acid from human platelets. A key role for the potentiation of platelet hyperaggregability in normal subjects as well as in those with nephrotic syndrome. Blood. 1978; 52:969-77.
32. Remuzzi G, Mecca G, Marchesi D, Livio M, de Gaetano G, Donati MB, et al. Platelet hyperaggregability and the nephrotic syndrome. Thromb Res. 1979; 16:345-54.
33. Sagripanti A, Barsotti G. Bleeding and thrombosis in chronic uremia. Nephron. 1997; 75:125-39.
34. Kim SB, Yang WS, Kang ES, Min WK, Park JS. Lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease. Perit Dial Int. 1997; 17:236-42.
35. Williams WR, Pawlowicz A, Davies B. Serum albumin and mortality. Lancet. 1990; 335:348-9.
36. Schieppati A, Dodesini P, Benigni A, Massazza M, Mecca G, Remuzzi G, et al. The metabolism of arachidonic acid by platelets in nephrotic syndrome. Kidney Int. 1984; 25:671-6.
37. Duniec Z, Robak J. Albumin is one of lipooxygenase inhibitors in serum. Pol J Pharmacol. 1984; 36:465-71.
38. Gotlieb AI, Langille BL. The role of rheology in atherosclerotic coronary artery disease. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. 1st ed. Philadelphia: Lippincott-Raven; 1996:595-606.
39. Groth CG. The effect of infused albumin and Rheomacrodex on factors governing the flow properties of the human blood. Acta Chir Scand. 1966; 131:290-7.
40. McGinley E, Lowe GDO, Boulton-Jones M, Forbes CD, Prentice CRM. Blood viscosity and haemostasis in the nephrotic syndrome. Thromb Haemost. 1983; 49:155-7.
41. Joles JA, Willekes-Koolschijn N, Koomans HA. Hypoalbuminemia causes high blood viscosity by increasing red cell lysophosphatidylcholine. Kidney Int. 1997; 52:761-70.
42. Feriani M, Kimmel PL, Kurantsin-Mills J, Bosch JP. Effect of renal replacement therapy on viscosity in end-stage renal disease patients. Am J Kidney Dis. 1992; 19:131-9.
43. Gordge MP, Patel A, Faint RW, Rylance PB, Neild GH. Blood hyperviscosity and its relationship to progressive renal failure in patients with diabetic nephropathy. Diabet Med. 1990; 7:880-6.
44. Fleck A. Acute phase response: Implications for nutrition and recovery. Nutrition. 1988; 4:109-17.
45. Yeun JY, Kaysen GA. Acute phase proteins and peritoneal dialysate albumin loss are the main determinants of serum albumin in peritoneal dialysis patients. Am J Kidney Dis. 1997; 30:923-7.
46. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: Is there a link? Lancet. 1997; 350:430-6.
47. Lip GYH, Lowe GDO, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: Effects of warfarin treatment. Br Heart J. 1995; 73:527-33.
48. Boneu B, Abbal M, Plante J, Bierme R. Factor VIII complex and endothelial damage. Lancet. 1975; 1:1430.
49. Oikawa T, Muramatsu Y, Akashi S, Usui N. A coagulation of fibrinolytic study in children with nephrotic syndrome: Evaluation of hypercoagulability by measuring with plasmin-alpha 2 plasmin inhibitor complex and FDP D-dimer. Jpn J Nephrol. 1997; 39:144-9.
50. Folsom AR, Ma J, Eckfeldt JH, Nieto FJ, Metcalf PA, Barnes RW. Low serum albumin. Association with diabetes mellitus and other cardiovascular risk factors but not with prevalent cardiovascular disease or carotid artery intima-media thickness. Ann Epidemiol. 1995; 5:186-91.
51. Beckham JC, Caldwell DS, Peterson BL, Pippen AM, Currie MS, Keefe FJ, et al. Disease severity in rheumatoid arthritis: Relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol. 1992; 12:353-61.
52. Blann AD. Von Willebrand factor as a marker of injury to the endothelium in inflammatory vascular disease. J Rheumatol. 1993; 20:1469-71.
53. Das I. Raised C-reactive protein levels in serum from smokers. Clin Chim Acta. 1985; 153:9-13.
54. Cha MK, Kim IH. Glutathione-linked thiol peroxidase activity of human serum albumin: A possible antioxidant role of serum albumin in blood plasma. Biochem Biophys Res Commun. 1996; 222:619-25.
55. Soejima A, Matuzawa N, Yoshida T, Kitamoto K, Nagasawa T. Hypoalbuminemia accelerates erythrocyte membrane lipid peroxidation in chronic hemodialysis patients [Abstract]. Nephrology. 1997; 3(Suppl 1):S289.
56. Nagai T, Kuriyama M, Kawada Y. Oxidative metabolism of polymorphonuclear leukocytes in continuous ambulatory peritoneal dialysis. Perit Dial Int. 1997; 17:167-74.
57. Jorgensen KA, Stoffersen E. Heparin like activity of albumin. Thromb Res. 1979; 16:569-74.
58. Degoulet P, Legrain M, Reach J, Aime F, Devries C, Rojas P, et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane Collaboratory Study. Nephron. 1982; 31:103-10.
59. Suliman ME, Qureshi AR, Anderstam B, Gutierrez A, Lindholm B, Bergström J. Plasma homocysteine is influenced by nutritional status in hemodialysis patients [Abstract]. J Am Soc Nephrol. 1996; 7:1325.